Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study

Fanale, Michelle A.; Kline, Justin; Chen, R.; Ribrag, V.; Salles, Gilles; Matsumura, Itaru; Zhu, Ying; Ricart, Alejandro D.; Balakumaran, Arun; Zinzani, P. L.

doi:10.1093/annonc/mdw375.42

Search citation statements

Order By: Relevance

Paper Sections

Select...

Rituximab1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94,95 Pembrolizumab is currently undergoing a direct comparison with brentuximab vedotin in the phase III randomised KEYNOTE-204 trial (NCT02684292) in patients with relapsed or refractory Hodgkin lymphoma. 96 Pembrolizumab is under investigation as combination therapy with the bispecific anti-CD30/CD16A antibody AFM13 (NCT02665650), the immunomodulatory agent lenalidomide in patients with relapsed Hodgkin lymphoma (NCT02875067), the histone deacetylase (HDAC) inhibitors vorinostat (NCT03150329) and entinostat (NCT03179930) in patients with relapsed/refractory Hodgkin lymphoma. A potential synergy between anti-PD-1 agents and the T-cell boosting activity of decitabine has also been revealed in a phase II study of the anti-PD-1 agent camrelizumab in patients with relapsed or refractory Hodgkin lymphoma.…”

Section: Rituximabmentioning

confidence: 99%